Progenra, Inc.
PrivateLast Round
Grant
May 16, 2025
Total Funding Raised
$7.81M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Progenra, Inc. is a biotechnology company that develops novel therapeutics targeting the ubiquitin-proteasome system, including molecular glues and targeted protein degradation for neurodegenerative, cardiovascular, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Progenra, Inc. Comparables
Compare Progenra, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SEED Therapeutics | 85% | |
| GluBio Therapeutics | 83% | |
| Dunad Therapeutics | 81% |
Progenra, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 16, 2025 | ||||
| Grant | Sep 20, 2024 | ||||
| Grant | Sep 1, 2022 | ||||
| Grant | Sep 1, 2020 | ||||
| Grant | May 26, 2020 |
Key People
Founding team and executive leadership
Progenra, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 2, 2026
Grew 33% QoQ from 9 to 12 employees.
- Jul 24, 2026
Monthly visitors increased 36% MoM, reaching 2.4K.
Progenra, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Progenra, Inc.'s valuation, stock price, and market status.
Is Progenra, Inc. a public or private company?
Progenra, Inc. is a private company.
What is the current stock price of Progenra, Inc.?
Progenra, Inc. is a private company, so its shares have no public market price. Caplight tracks Progenra, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Progenra, Inc. worth (valuation)?
Valuation information for Progenra, Inc. is not publicly available.
Can I buy Progenra, Inc. stock?
Progenra, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Progenra, Inc.'s last funding round?
Progenra, Inc.'s most recent funding round was Grant on May 16, 2025.
Who are the main investors in Progenra, Inc.?
Key investors in Progenra, Inc. include U.S. Department of Health and Human Services, The Michael J. Fox Foundation for Parkinson's Research.
Will Progenra, Inc. IPO soon?
No public IPO plans have been announced for Progenra, Inc..
How can I track Progenra, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Progenra, Inc.'s shares on secondary markets.